A TRPC4-specific agonist, should it be developed, might therefore be an approach for achieving an anti-cancer effect with tolerable toxicity, but careful dose-dependency studies would be needed with a stable analogue of the agonist before clinical trials could reasonably be considered. Here, TRPC4 is linked to cancer.